Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1954285 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL10633018 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL868782 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL8031217 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL10427141 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL33526075 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL491780 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL867932 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL6088399 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL19271810 | 0.98 | NOS3 (0.43) | NOS3NOS1DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214827-A1 | For severe and chronic pain; 1-(1-Cyclooctyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-ylidene-cyanamide and 2-[2-Cyanoimino-3-(1-cyclooctyl-piperidin-4-yl)-2,3-dihydro-benzoimidazol-1-yl]-acetamide | EURO-CELTIQUE S.A. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1711484-A4 | SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES | EURO CELTIQUE SA (LU) | 2007-06-20 | — | — | EP | disclosed |
| EP-1711484-A1 | SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES | EURO-CELTIQUE S.A. (LU) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005075459-A1 | SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES | EURO-CELTIQUE S.A. (LU) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214827-A1 | For severe and chronic pain; 1-(1-Cyclooctyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-ylidene-cyanamide and 2-[2-Cyanoimino-3-(1-cyclooctyl-piperidin-4-yl)-2,3-dihydro-benzoimidazol-1-yl]-acetamide | CNR2, CNR1, TRPV1 | NOS3 339/4885NOS1 449/4885DPP4 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.